NIT
BCRX icon

NumerixS Investment Technologies’s BioCryst Pharmaceuticals BCRX Stock Holding History

NumerixS Investment Technologies’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-22,200
Closed -$116K – 1137
2017
Q3 		$116K Sell
22,200
-13,000
-37% -$66.6K 0.03% 702
2017
Q2 		$196K Buy
+35,200
New +$214K 0.03% 644

Other funds holding BCRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

NumerixS Investment Technologies's BCRX Position: Q4 2017 in Review

NumerixS Investment Technologies sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2017, closing a stake of 22,200 shares — an estimated $116K sold.

NumerixS Investment Technologies first reported a position in BCRX in Q2 2017 and held it in 2 quarters. The position peaked at $196K in Q2 2017. 116 funds tracked by Wall St. Rank hold BCRX as of Q4 2017.

  • NumerixS Investment Technologies reported no remaining BioCryst Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • NumerixS Investment Technologies sold 22,200 BioCryst Pharmaceuticals shares in Q4 2017, an estimated $116K.
  • NumerixS Investment Technologies first reported a position in BioCryst Pharmaceuticals in Q2 2017 and held it in 2 quarters.
  • NumerixS Investment Technologies's BioCryst Pharmaceuticals position peaked at $196K in Q2 2017.
  • 116 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2017.

Based on NumerixS Investment Technologies's 13F filing for Q4 2017, filed 13 Feb 2018.